ファーマコビジランス市場-タイプ別（ソフトウェア、サービス｛プロセス別、活動別［自発報告、副作用報告強化、コホートイベント監視］｝）、臨床試験フェーズ別、サービスプロバイダー別、最終用途別、予測、2023-2032年

世界のファーマコビジランス市場は、医薬品安全性監視の需要の高まりと、患者の安全を確保するためのデータ駆動型インサイトの必要性によって、2023年から2032年にかけて著しい成長を示すと予想されています。

また、医薬品承認に関する厳しい規制要件に沿った新薬や革新的な医薬品への需要の高まりが、今後10年間の市場成長を促進すると考えられます。

薬物有害反応（ADR）や薬物毒性の発生率の上昇は、ファーマコビジランスの需要を促進しています。これらの治療薬は多様化し、入手しやすくなっているため、その安全性と有効性を注意深く監視する必要があります。医薬品の利点が起こりうる危険性を上回ることを保証するファーマコビジランスの重要性が、製品採用を後押ししています。さらに、世界人口の一貫した急増と慢性疾患の有病率の増加も、医薬品安全性の必要性を後押ししています。CDCによると、毎年約877,500人のアメリカ人が心臓発作で死亡しています。

疾病負担の増大と、業界をリードするために有望なパートナーシップや合併に注力する主要市場プレイヤーの増加は、市場成長に有利に働くでしょう。例えば、2023年4月、ドイツの製薬会社であるPharmaLexは、オーストラリアとニュージーランドのファーマコビジランスプロバイダーであるCpharmと戦略的合併を発表しました。この提携により、両社はオーストラリア市場でエンドツーエンドのソリューションを提供し、医療サービス＆顧客基盤を拡大することを目指しています。

ファーマコビジランス市場は、タイプ、臨床試験段階、サービスプロバイダー、最終用途、地域の観点から二分されます。

臨床試験フェーズに基づくと、フェーズ2セグメントは2032年末までに4億1,000万米ドル超に達すると予想されます。この第2相試験は、対象となる疾患や症状を持つより多くの患者を対象に、医薬品候補の安全性と有効性を評価するために実施されるものです。世界中で臨床試験の数が増加しているため、これらの試験中の患者の安全性を監視し確保するための強固なファーマコビジランスシステムの必要性が高まっています。

最終用途に関しては、医療機器企業セグメントによるファーマコビジランスの市場価値は、2022年に25億米ドル以上となっています。ファーマコビジランスサービスプロバイダーは、単一の有害事象の処理と報告から、フィールド安全是正措置の一環としての製品の市場からの撤退まで、医療機器の安全プロファイルを企業に供給します。規制当局が医療機器の市販後調査や安全性監視をより重視していることが、製品の普及を後押ししています。

アジア太平洋地域のファーマコビジランス市場は、2023年から2032年にかけて顕著なCAGRを示すと予想されています。これは、多数のアウトソーシング機関が存在することに起因しています。生産性の向上、コスト効率、リソースの共有化により、今後数年間はファーマコビジランスの地域的需要が高まると予想されます。さらに、薬物摂取量とヘルスケア需要の増加に伴う人口基盤の拡大も、地域の市場成長を補完しています。

目次

第1章 調査手法とスコープ

第2章 エグゼクティブサマリー

第3章 ファーマコビジランス業界洞察

• 業界のセグメンテーション
• 業界情勢、2018年～2032年
• 業界への影響要因
  • 促進要因
    • 新薬のニーズの高まり
    • 製薬会社別研究開発への投資の増加
    • 薬物有害反応（ADR）および薬物毒性の発生件数の増加
    • 個別化医療への注目の高まり
    • ファーマコビジランス・サービスのアウトソーシングの動向の増加
  • 業界の潜在的リスク＆課題
    • データセキュリティに関連する高いリスク
    • 熟練したヘルスケア専門家の不足
• 成長可能性分析
  • タイプ別
  • 臨床試験フェーズ別
  • サービスプロバイダー別
  • 最終用途別
• COVID-19の影響分析
• 規制状況
  • 米国
  • 欧州
• テクノロジー・情勢
  • ファーマコビジランスにおける人工知能（AI）
  • ファーマコビジランスにおける自然言語処理（NLP）
• ポーター分析
• PESTEL分析

第4章 競合情勢、2022年

• イントロダクション
• 企業マトリックス分析、2022年
• 各社のポジショニングマトリックス
• 主要市場プレイヤーの競合分析
• 戦略的展望マトリクス
• 企業シェア分析、2022年
• 戦略ダッシュボード（2022年

第5章 ファーマコビジランス市場：タイプ別

• 主なタイプ別動向
• ソフトウェア
• サービス
  • プロセス別
    • コアサービス
    • コンサルティングサービス
  • 活動別
    • 自発的な報告
    • 副作用（ADR）報告の強化
    • コホートイベント監視
    • EHRマイニング
    • その他

第6章 ファーマコビジランス市場：臨床試験フェーズ別

• 主な臨床試験フェーズ別の動向
• 前臨床試験
• フェーズ1
• フェーズ2
• フェーズ3
• フェーズ4

第7章 ファーマコビジランス市場：サービスプロバイダー別

• 主なサービスプロバイダー動向
• インハウス
• アウトソーシング受託

第8章 ファーマコビジランス市場：エンドユーズ別

• 主な最終用途の動向
• 製薬・バイオテクノロジー企業
• 医療機器メーカー
• 病院
• その他

第9章 ファーマコビジランス市場：地域別

• 主な地域動向
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
  • その他ラテンアメリカ地域
• 中東＆アフリカ
  • 南アフリカ共和国
  • サウジアラビア
  • UAE
  • カタール
  • イスラエル
  • その他中東とアフリカ

第10章 企業プロファイル

• Accenture
• Cognizant
• Labcorp Drug Development
• IBM Corporation
• ArisGlobal
• ICON plc
• United BioSource LLC
• Pharmaceutical Development Group, Inc.
• Wipro Limited
• Allucent

Data Tables

• TABLE 1. Market revenue, by type, 2022
• TABLE 2. Market revenue, by clinical trial phase, 2022
• TABLE 3. Market revenue, by service provider, 2022
• TABLE 4. Market revenue, by end-use, 2022
• TABLE 5. Market share, by region, 2022
• TABLE 6. Global pharmacovigilance market, 2018-2022 (USD Million)
• TABLE 7. Global pharmacovigilance market, 2023 - 2032 (USD Million)
• TABLE 8. Global pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 9. Global pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 10. Global pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 11. Global pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 12. Global pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 13. Global pharmacovigilance market, by service provider, 2023 - 2032 (USD Million)
• TABLE 14. Global pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 15. Global pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 16. Global pharmacovigilance market, region, 2018-2022 (USD Million)
• TABLE 17. Global pharmacovigilance market, region, 2023 - 2032 (USD Million)
• TABLE 18. Industry impact forces
• TABLE 19. Software market estimates and forecast, 2018-2022 (USD Million)
• TABLE 20. Software market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 21. Service market estimates and forecast, 2018-2022 (USD Million)
• TABLE 22. Service market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 23. Core services market estimates and forecast, 2018-2022 (USD Million)
• TABLE 24. Core services market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 25. Consulting services market estimates and forecast, 2018-2022 (USD Million)
• TABLE 26. Consulting services market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 27. Spontaneous reporting market estimates and forecast, 2018-2022 (USD Million)
• TABLE 28. Spontaneous reporting market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 29. Intensified Adverse Drug Reaction (ADR) reporting market estimates and forecast, 2018-2022 (USD Million)
• TABLE 30. Intensified Adverse Drug Reaction (ADR) reporting market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 31. Cohort event monitoring market estimates and forecast, 2018-2022 (USD Million)
• TABLE 32. Cohort event monitoring market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 33. EHR mining market estimates and forecast, 2018-2022 (USD Million)
• TABLE 34. EHR mining market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 35. Other activities market estimates and forecast, 2018-2022 (USD Million)
• TABLE 36. Other activities market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 37. Pre-clinical animals market estimates and forecast, 2018-2022 (USD Million)
• TABLE 38. Pre-clinical animals market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 39. Phase 1 market estimates and forecast, 2018-2022 (USD Million)
• TABLE 40. Phase 1 market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 41. Phase 2 market estimates and forecast, 2018-2022 (USD Million)
• TABLE 42. Phase 2 market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 43. Phase 3 market estimates and forecast, 2018-2022 (USD Million)
• TABLE 44. Phase 3 market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 45. Phase 4 and goats market estimates and forecast, 2018-2022 (USD Million)
• TABLE 46. Phase 4 and goats market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 47. In-house market estimates and forecast, 2018-2022 (USD Million)
• TABLE 48. In-house market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 49. Contract outsourcing market estimates and forecast, 2018-2022 (USD Million)
• TABLE 50. Contract outsourcing market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 51. Pharmaceutical & biotechnological companies market estimates and forecast, 2018-2022 (USD Million)
• TABLE 52. Pharmaceutical & biotechnological companies market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 53. Medical device companies market estimates and forecast, 2018-2022 (USD Million)
• TABLE 54. Medical device companies market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 55. Hospitals market estimates and forecast, 2018-2022 (USD Million)
• TABLE 56. Hospitals market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 57. Others market estimates and forecast, 2018-2022 (USD Million)
• TABLE 58. Others market estimates and forecast, 2023 - 2032 (USD Million)
• TABLE 59. North America pharmacovigilance market, by country, 2018-2022 (USD Million)
• TABLE 60. North America pharmacovigilance market, by country, 2023 - 2032 (USD Million)
• TABLE 61. North America pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 62. North America pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 63. North America pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 64. North America pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 65. North America pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 66. North America pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 67. North America pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 68. North America pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 69. North America pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 70. North America pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 71. North America pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 72. North America pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 73. U.S. pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 74. U.S. pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 75. U.S. pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 76. U.S. pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 77. U.S. pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 78. U.S. pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 79. U.S. pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 80. U.S. pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 81. U.S. pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 82. U.S. pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 83. U.S. pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 84. U.S. pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 85. Canada pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 86. Canada pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 87. Canada pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 88. Canada pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 89. Canada pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 90. Canada pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 91. Canada pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 92. Canada pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 93. Canada pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 94. Canada pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 95. Canada pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 96. Canada pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 97. Europe pharmacovigilance market, by country, 2018-2022 (USD Million)
• TABLE 98. Europe pharmacovigilance market, by country, 2023 - 2032 (USD Million)
• TABLE 99. Europe pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 100. Europe pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 101. Europe pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 102. Europe pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 103. Europe pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 104. Europe pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 105. Europe pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 106. Europe pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 107. Europe pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 108. Europe pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 109. Europe pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 110. Europe pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 111. Germany pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 112. Germany pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 113. Germany pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 114. Germany pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 115. Germany pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 116. Germany pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 117. Germany pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 118. Germany pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 119. Germany pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 120. Germany pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 121. Germany pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 122. Germany pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 123. UK pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 124. UK pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 125. UK pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 126. UK pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 127. UK pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 128. UK pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 129. UK pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 130. UK pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 131. UK pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 132. UK pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 133. UK pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 134. UK pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 135. France pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 136. France pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 137. France pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 138. France pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 139. France pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 140. France pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 141. France pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 142. France pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 143. France pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 144. France pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 145. France pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 146. France pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 147. Italy pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 148. Italy pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 149. Italy pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 150. Italy pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 151. Italy pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 152. Italy pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 153. Italy pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 154. Italy pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 155. Italy pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 156. Italy pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 157. Italy pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 158. Italy pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 159. Spain pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 160. Spain pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 161. Spain pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 162. Spain pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 163. Spain pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 164. Spain pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 165. Spain pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 166. Spain pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 167. Spain pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 168. Spain pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 169. Spain pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 170. Spain pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 171. Rest of Europe pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 172. Rest of Europe pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 173. Rest of Europe pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 174. Rest of Europe pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 175. Rest of Europe pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 176. Rest of Europe pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 177. Rest of Europe pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 178. Rest of Europe pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 179. Rest of Europe pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 180. Rest of Europe pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 181. Rest of Europe pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 182. Rest of Europe pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 183. Asia Pacific pharmacovigilance market, by country, 2018-2022 (USD Million)
• TABLE 184. Asia Pacific pharmacovigilance market, by country, 2023 - 2032 (USD Million)
• TABLE 185. Asia Pacific pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 186. Asia Pacific pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 187. Asia Pacific pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 188. Asia Pacific pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 189. Asia Pacific pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 190. Asia Pacific pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 191. Asia Pacific pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 192. Asia Pacific pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 193. Asia Pacific pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 194. Asia Pacific pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 195. Asia Pacific pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 196. Asia Pacific pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 197. China pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 198. China pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 199. China pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 200. China pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 201. China pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 202. China pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 203. China pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 204. China pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 205. China pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 206. China pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 207. China pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 208. China pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 209. India pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 210. India pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 211. India pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 212. India pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 213. India pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 214. India pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 215. India pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 216. India pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 217. India pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 218. India pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 219. India pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 220. India pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 221. Japan pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 222. Japan pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 223. Japan pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 224. Japan pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 225. Japan pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 226. Japan pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 227. Japan pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 228. Japan pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 229. Japan pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 230. Japan pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 231. Japan pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 232. Japan pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 233. Australia pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 234. Australia pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 235. Australia pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 236. Australia pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 237. Australia pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 238. Australia pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 239. Australia pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 240. Australia pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 241. Australia pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 242. Australia pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 243. Australia pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 244. Australia pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 245. Rest of Asia Pacific pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 246. Rest of Asia Pacific pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 247. Rest of Asia Pacific pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 248. Rest of Asia Pacific pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 249. Rest of Asia Pacific pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 250. Rest of Asia Pacific pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 251. Rest of Asia Pacific pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 252. Rest of Asia Pacific pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 253. Rest of Asia Pacific pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 254. Rest of Asia Pacific pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 255. Rest of Asia Pacific pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 256. Rest of Asia Pacific pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 257. Latin America pharmacovigilance market, by country, 2018-2022 (USD Million)
• TABLE 258. Latin America pharmacovigilance market, by country, 2023 - 2032 (USD Million)
• TABLE 259. Latin America pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 260. Latin America pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 261. Latin America pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 262. Latin America pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 263. Latin America pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 264. Latin America pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 265. Latin America pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 266. Latin America pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 267. Latin America pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 268. Latin America pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 269. Latin America pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 270. Latin America pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 271. Brazil pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 272. Brazil pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 273. Brazil pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 274. Brazil pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 275. Brazil pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 276. Brazil pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 277. Brazil pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 278. Brazil pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 279. Brazil pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 280. Brazil pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 281. Brazil pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 282. Brazil pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 283. Mexico pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 284. Mexico pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 285. Mexico pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 286. Mexico pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 287. Mexico pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 288. Mexico pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 289. Mexico pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 290. Mexico pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 291. Mexico pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 292. Mexico pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 293. Mexico pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 294. Mexico pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 295. Argentina pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 296. Argentina pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 297. Argentina pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 298. Argentina pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 299. Argentina pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 300. Argentina pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 301. Argentina pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 302. Argentina pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 303. Argentina pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 304. Argentina pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 305. Argentina pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 306. Argentina pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 307. Rest of Latin America pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 308. Rest of Latin America pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 309. Rest of Latin America pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 310. Rest of Latin America pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 311. Rest of Latin America pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 312. Rest of Latin America pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 313. Rest of Latin America pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 314. Rest of Latin America pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 315. Rest of Latin America pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 316. Rest of Latin America pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 317. Rest of Latin America pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 318. Rest of Latin America pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 319. MEA pharmacovigilance market, by country, 2018-2022 (USD Million)
• TABLE 320. MEA pharmacovigilance market, by country, 2023 - 2032 (USD Million)
• TABLE 321. MEA pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 322. MEA pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 323. MEA pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 324. MEA pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 325. MEA pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 326. MEA pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 327. MEA pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 328. MEA pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 329. MEA pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 330. MEA pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 331. MEA pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 332. MEA pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 333. South Africa pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 334. South Africa pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 335. South Africa pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 336. South Africa pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 337. South Africa pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 338. South Africa pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 339. South Africa pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 340. South Africa pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 341. South Africa pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 342. South Africa pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 343. South Africa pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 344. South Africa pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 345. Saudi Arabia pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 346. Saudi Arabia pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 347. Saudi Arabia pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 348. Saudi Arabia pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 349. Saudi Arabia pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 350. Saudi Arabia pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 351. Saudi Arabia pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 352. Saudi Arabia pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 353. Saudi Arabia pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 354. Saudi Arabia pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 355. Saudi Arabia pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 356. Saudi Arabia pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 357. UAE pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 358. UAE pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 359. UAE pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 360. UAE pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 361. UAE pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 362. UAE pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 363. UAE pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 364. UAE pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 365. UAE pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 366. UAE pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 367. UAE pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 368. UAE pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 369. Qatar pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 370. Qatar pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 371. Qatar pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 372. Qatar pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 373. Qatar pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 374. Qatar pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 375. Qatar pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 376. Qatar pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 377. Qatar pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 378. Qatar pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 379. Qatar pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 380. Qatar pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 381. Israel pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 382. Israel pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 383. Israel pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 384. Israel pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 385. Israel pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 386. Israel pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 387. Israel pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 388. Israel pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 389. Israel pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 390. Israel pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 391. Israel pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 392. Israel pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
• TABLE 393. Rest of Middle East & Africa pharmacovigilance market, by type, 2018-2022 (USD Million)
• TABLE 394. Rest of Middle East & Africa pharmacovigilance market, by type, 2023 - 2032 (USD Million)
• TABLE 395. Rest of Middle East & Africa pharmacovigilance market, by process, 2018-2022 (USD Million)
• TABLE 396. Rest of Middle East & Africa pharmacovigilance market, by process, 2023-2032 (USD Million)
• TABLE 397. Rest of Middle East & Africa pharmacovigilance market, by activity, 2018-2022 (USD Million)
• TABLE 398. Rest of Middle East & Africa pharmacovigilance market, by activity, 2023-2032 (USD Million)
• TABLE 399. Rest of Middle East & Africa pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
• TABLE 400. Rest of Middle East & Africa pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
• TABLE 401. Rest of Middle East & Africa pharmacovigilance market, by service provider, 2018-2022 (USD Million)
• TABLE 402. Rest of Middle East & Africa pharmacovigilance market, by service provider, 2023-2032 (USD Million)
• TABLE 403. Rest of Middle East & Africa pharmacovigilance market, by end-use, 2018-2022 (USD Million)
• TABLE 404. Rest of Middle East & Africa pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)

Charts & Figures

• FIG. 1 GMI report coverage: Critical research elements
• FIG. 2 Industry segmentation
• FIG. 3 Top-down approach
• FIG. 4 Market estimation and forecast methodology
• FIG. 5 Market forecasting methodology
• FIG. 6 Breakdown of primary participants
• FIG. 7 Global pharmacovigilance industry 360 degree synopsis, 2018 - 2032 (USD Mn)
• FIG. 8 Growth potential analysis, by type
• FIG. 9 Growth potential analysis, by clinical trial phase
• FIG. 10 Growth potential analysis, by service provider
• FIG. 11 Growth potential analysis, by end-use
• FIG. 12 Company matrix analysis
• FIG. 13 Competitive analysis of major market players
• FIG. 14 Competitive positioning matrix
• FIG. 15 Strategic outlook matrix
• FIG. 16 Company market share analysis, 2022
• FIG. 17 Strategic dashboard

Global Pharmacovigilance Market is expected to showcase remarkable growth over 2023-2032, driven by the increasing demand for drug safety monitoring and the need for data-driven insights to ensure patient safety. In addition, increasing demand for new and innovative drugs, in line with stringent regulatory requirements for drug approval, will fuel market growth over the next ten years.

The rising incidence rate of adverse drug reactions (ADR) and drug toxicity is encouraging the demand for pharmacovigilance. The safety and effectiveness of these treatments need to be closely monitored, given their increasing diversity and availability. The importance of pharmacovigilance in ensuring that the advantages of medicines outweigh any possible hazards is pushing product adoption. Moreover, the consistent surge in the global population and increased prevalence of chronic diseases have also propelled the need for drug safety. According to CDC, around 877.500 Americans die of heart strokes each year.

The growing disease burden and the increasing focus of key market players on promising partnerships and mergers to stay ahead in the industry will favor market growth. For instance, in April 2023, PharmaLex, a German pharmaceutical firm, announced a strategic merger with Cpharm, a pharmacovigilance provider in Australia and New Zealand. With this alliance, the companies aim to offer end-to-end solutions in the Australian market and expand their medical services & customer base.

The pharmacovigilance market is bifurcated in terms of type, clinical trial phase, service provider, end-use, and region.

Based on the clinical trial phase, the phase 2 segment is expected to reach over $410 million by the end of 2032. This second stage of trials is conducted to evaluate the safety and efficacy of a drug candidate in a larger group of patients with the target disease or condition. The rising number of clinical trials worldwide is fueling the need for robust pharmacovigilance systems to monitor and ensure patient safety during these trials.

With respect to end-use, the pharmacovigilance market value from the medical device companies segment was over $2.5 billion in 2022. Pharmacovigilance service providers supply medical device safety profiles to companies, ranging from the processing and reporting of single adverse incidents through the withdrawal of products from the market as part of a Field Safety Corrective Action. The greater emphasis of regulatory bodies on post-market surveillance and safety monitoring of medical devices is bolstering product uptake.

Asia Pacific pharmacovigilance market is expected to exhibit an appreciable CAGR between 2023 and 2032, attributed to the availability of numerous outsourcing organizations. The increasing productivity, cost efficiency, and resource sharing are expected to drive regional demand for pharmacovigilance in the upcoming years. Additionally, the expanding population base with increased drug intake and healthcare demand are also complementing the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Industry coverage
• 1.2 Market scope and definitions
• 1.3 Base estimates and working
• 1.4 Forecast parameters
• 1.5 COVID-19 impact analysis at global level
• 1.6 Data validation
• 1.7 Data sources
  • 1.7.1 Primary
  • 1.7.2 Secondary
    • 1.7.2.1 Paid sources
    • 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Pharmacovigilance industry 360 degree synopsis, 2018 - 2032
  • 2.1.1 Business trends
  • 2.1.2 Type trends
  • 2.1.3 Clinical trial phase trends
  • 2.1.4 Service provider trends
  • 2.1.5 End-user trends
  • 2.1.6 Regional trends

Chapter 3 Pharmacovigilance Industry Insights

• 3.1 Industry segmentation
• 3.2 Industry landscape, 2018 - 2032
• 3.3 Industry impact forces
  • 3.3.1 Growth drivers
    • 3.3.1.1 Increasing need of new drugs
    • 3.3.1.2 Rising investment on R&D by pharmaceutical companies
    • 3.3.1.3 Rise in incidences of adverse drug reactions (ADR) and drug toxicity
    • 3.3.1.4 Increasing focus on personalized medicine
    • 3.3.1.5 Increasing trend of outsourcing pharmacovigilance services
  • 3.3.2 Industry pitfalls & challenges
    • 3.3.2.1 High risk associated with data security
    • 3.3.2.2 Lack of skilled healthcare professionals
• 3.4 Growth potential analysis
  • 3.4.1 By type
  • 3.4.2 By clinical trial phase
  • 3.4.3 By service provider
  • 3.4.4 By end-use
• 3.5 COVID-19 impact analysis
• 3.6 Regulatory landscape
  • 3.6.1 U.S.
  • 3.6.2 Europe
• 3.7 Technology landscape
  • 3.7.1 Artificial intelligence (AI) in pharmacovigilance
  • 3.7.2 Natural language processing (NLP) in pharmacovigilance
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis, 2022
• 4.3 Company positioning matrix
• 4.4 Competitive analysis of major market players
• 4.5 Strategic outlook matrix
• 4.6 Company market share analysis, 2022
• 4.7 Strategy dashboard, 2022

Chapter 5 Pharmacovigilance Market, By Type

• 5.1 Key type trends
• 5.2 Software
  • 5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
• 5.3 Service
  • 5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
  • 5.3.2 By Process
    • 5.3.2.1 Core services
      • 5.3.2.1.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 5.3.2.2 Consulting services
      • 5.3.2.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
  • 5.3.3 By Activity
    • 5.3.3.1 Spontaneous Reporting
      • 5.3.3.1.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 5.3.3.2 Intensified Adverse Drug Reaction (ADR) Reporting
      • 5.3.3.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 5.3.3.3 Cohort Event Monitoring
      • 5.3.3.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 5.3.3.4 EHR Mining
      • 5.3.3.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 5.3.3.5 Others
      • 5.3.3.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 6 Pharmacovigilance Market, By Clinical Trial Phase

• 6.1 Key clinical trial phase trends
• 6.2 Pre-clinical
  • 6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
• 6.3 Phase 1
  • 6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
• 6.4 Phase 2
  • 6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
• 6.5 Phase 3
  • 6.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
• 6.6 Phase 4
  • 6.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 7 Pharmacovigilance Market, By Service Provider

• 7.1 Key service provider trends
• 7.2 In-house
  • 7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
• 7.3 Contract outsourcing
  • 7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 8 Pharmacovigilance Market, By End-use

• 8.1 Key end-use trends
• 8.2 Pharmaceutical & biotechnological companies
  • 8.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
• 8.3 Medical device companies
  • 8.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
• 8.4 Hospitals
  • 8.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
• 8.5 Others
  • 8.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 9 Pharmacovigilance Market, By Region

• 9.1 Key regional trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East & Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Qatar
  • 9.6.5 Israel
  • 9.6.6 Rest of Middle East & Africa

Chapter 10 Company Profiles

• 10.1 Accenture
• 10.2 Cognizant
• 10.3 Labcorp Drug Development
• 10.4 IBM Corporation
• 10.5 ArisGlobal
• 10.6 ICON plc
• 10.7 United BioSource LLC
• 10.8 Pharmaceutical Development Group, Inc.
• 10.9 Wipro Limited
• 10.10 Allucent